Given the role of NK cells in cancer cell killing and the dual role of CD94 (both inhibitory and activating), CD94 has emerged as a therapeutic target in humans, both within the tumor immune microenvironment as well as directly targeting tumors of cytotoxic cell origin (16–18). The gene discussed is KLRD1; the disease is neoplasm.